Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Still a Buy?

Autolus Therapeutics plc (NASDAQ:AUTL) shares gapped up before the market opened on Monday . The stock had previously closed at $3.08, but opened at $3.24. Autolus Therapeutics shares last traded at $3.07, with a volume of 285,730 shares changing hands.

Analyst Upgrades and Downgrades

AUTL has been the topic of several analyst reports. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $7.00 to $7.60 in a research note on Monday. Finally, Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Trading Down 1.3 %

The business has a 50 day moving average price of $3.86 and a 200-day moving average price of $3.97. The firm has a market capitalization of $784.97 million, a PE ratio of -2.44 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the business earned ($0.26) earnings per share. On average, equities research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AUTL. ProShare Advisors LLC purchased a new position in Autolus Therapeutics in the second quarter valued at about $43,000. Capstone Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the 3rd quarter worth approximately $51,000. Bayesian Capital Management LP purchased a new position in shares of Autolus Therapeutics in the first quarter valued at $100,000. Daiwa Securities Group Inc. increased its holdings in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $108,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.